Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Chemring can benefit from Trump’s Afghanistan push

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
US President Donald Trump’s impassioned speech to troops at Fort Myer military base in Arlington Virginia on 21 August is potentially encouraging for investors in munitions manufacturer Chemring (CHG).
His promise to ensure his troops ‘have every weapon to apply swift, decisive and overwhelming force’ could boost demand for the company’s products.
Sanjay Jha, analyst at Panmure Gordon, says: ‘Chemring should be the biggest beneficiary from a protracted war in Afghanistan and Pakistan involving increasing numbers of troops.’
Chemring’s offering
A ‘short cycle war’, as Jha dubs the US’s new strategy in Afghanistan, should play to Chemring’s strengths. Its countermeasures, improvised explosive device defences and pyrotechnics fit well with this style of warfare.
The company also produces some highly effective munitions including 40mm grenades as well as mortar shells which are suitable for land-based warfare.
The company’s chief executive Michael Flowers took over three years ago and the company has recovered from a period of multiple profit warnings. Jha says under the new management the company has been reducing its reliance on short cycle product.
But the countermeasures and energetic systems divisions still accounted for almost 80% of group sales last year and Jha says that a drawn out conflict ‘could lead to a sudden boost in volumes and margins’.
Jha gives Chemring a target price of 216p, implying 22% upside at the current price of 177p.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.